Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 6, Issue 5, 2025

Study on the Prognosis of Ischemic Stroke Patients with Dual Antiplatelet Therapy Based on P2Y12 Receptor Antagonist

Download as PDF

DOI: 10.23977/medsc.2025.060527 | Downloads: 0 | Views: 141

Author(s)

Yanbo Diao 1, Dongmei Zhang 1, Ying Guan 1

Affiliation(s)

1 Heihe First People's Hospital, Heihe, Heilongjiang, 164300, China

Corresponding Author

Yanbo Diao

ABSTRACT

This study investigated the clinical efficacy and safety of P2Y12 receptor antagonists combined with aspirin in the treatment of ischemic stroke patients. A randomized controlled trial was conducted, enrolling 300 ischemic stroke patients who were randomly assigned to either the experimental group (aspirin enteric-coated tablets and ticagrelor tablets) or the control group (aspirin enteric-coated tablets and clopidogrel bisulfate). The treatment lasted for 3 months, with assessments of functional recovery, stroke recurrence rate, and adverse drug reaction (ADR) incidence. The experimental group demonstrated superior outcomes compared to the control group in terms of functional recovery (mRS score: 2.3±1.2 vs. 3.5±1.4, P<0.001), stroke recurrence rate (4% vs. 10%, P=0.037), and ADR incidence (5.3% vs. 12%, P=0.043). The combination therapy of P2Y12 receptor antagonists (aspirin enteric-coated tablets and ticagrelor tablets) significantly improved functional recovery, reduced recurrence rates, and decreased ADR incidence in ischemic stroke patients, indicating promising clinical application prospects.

KEYWORDS

P2Y12 receptor antagonist; Ticagrelor tablets; Clopidogrel bisulfate tablets; Aspirin; Ischemic stroke; Functional recovery

CITE THIS PAPER

Yanbo Diao, Dongmei Zhang, Ying Guan, Study on the Prognosis of Ischemic Stroke Patients with Dual Antiplatelet Therapy Based on P2Y12 Receptor Antagonist. MEDS Clinical Medicine (2025) Vol. 6: 183-188. DOI: http://dx.doi.org/10.23977/medsc.2025.060527.

REFERENCES

[1] Shu Xuemei. Efficacy and safety of monotherapy versus dual antiplatelet therapy based on P2Y12R inhibitors in recent non-cardiogenic stroke or transient ischemic attack: a meta-analysis [D]. Huazhong University of Science and Technology, 2022.
[2] Yin T, Zou YT, Wu YX. A circRNA detection kit for predicting the antiplatelet efficacy of P2Y12 receptor antagonists and its application: CN202110521378.6[P]. CN113186273B[2025-12-25].
[3] Liu Yulan, Huang Fangyang, Chen Juan, et al. Advances in the application of P2Y12 receptor inhibitors in dual antiplatelet therapy after PCI in patients with acute myocardial infarction [J]. China Journal of Evidence-Based Cardiovascular Medicine, 2025,17(2):254-256.
[4] Li Xiaoxiang, Xu Ziao, Li Degang, et al. A guanidinium-containing P2Y12 receptor antagonist, preparation method and its application: CN201810115116.8[P]. CN110117257B[2025-12-25].
[5] Pei Yang, Li Yingkai, Yuan Shan. Research progress on P2Y12 receptor antagonist monotherapy for antiplatelet treatment after percutaneous coronary intervention [J]. China Modern Medicine Journal, 2021,23(2):5.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 10253
Visits: 762712

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.